Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- JPMA to Gear Up Efforts to Protect IP
October 7, 2002
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
October 7, 2002
- Dr Sakaguchi Shows Direction for Medical Fee System Reform: Economist Conferences
October 7, 2002
- Sales Up, But Gross Profit Margin Down 4.14%: FJPWA Survey
October 7, 2002
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
October 7, 2002
- Effects of Generics Use-Promotion Policy Remain Unpredictable: EMA
October 7, 2002
- Iino in Saitama Joins AEON Welcia Group
October 7, 2002
- BUSINESS NEWS IN BRIEF
October 7, 2002
- Association to Support Studies of Health Food in Humans
October 7, 2002
- Health Minister Presents Personal Proposals for Healthcare Reform
October 7, 2002
- Drug Retailers Should Promote Self-medication: NMRA Meeting
October 7, 2002
- Korosho to Reorganize PFSB
October 7, 2002
- DIAGNOSTIC NEWS IN BRIEF
October 7, 2002
- Mr Miyauchi Criticizes Korosho for Its Opposition to Deregulation
October 7, 2002
- Nippon Keidanren Calls For Simplification of Application for Medical Devices
October 7, 2002
- PFSB to Accelerate Introduction of Fast-Track System
October 7, 2002
- Olympus Sets Up Marketing Subsidiary in Sao Paulo
October 7, 2002
- Drugs for 21st Quality Reevaluation Announced
October 7, 2002
- Olympus: New Reaction/Analysis System FD10
October 7, 2002
- Results of Reexamination for 22 Active Ingredients Announced
October 7, 2002
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…